Loading…
TELA Bio, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -90.2% over 5Y.
today you would have $92.24▼ -90.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.18 | $3.02 | $6.62 | $11.50 | $12.80 | $15.04 | $12.95 | |
| P/S | 5.3x | 0.7x | 1.7x | 2.8x | 5.3x | 6.3x | 11.9x | 9.6x |
| P/B | 8.4x | 8.4x | 4.2x | 8.6x | 15.4x | 9.3x | 4.4x | 4.8x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MIRAMIRA Pharmaceuticals Inc | $0.75 | — | 3.9x | — | -217.12% | $31.52M |
| SCLXScilex Holding Co | $4.49 | — | — | — | — | $31.59M |
| NNVCNanoviricides Inc | $1.24 | — | 2.9x | — | -89.97% | $31.65M |
| ATNMActinium Pharmaceuticals, Inc. | $1.01 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Company description provided by Yahoo Finance.
| EPS | -$0.83 | -$1.33 | -$2.04 | -$2.72 | -$2.30 | -$2.23 | -$17.10 |
| Profit margin | -106.95% | -48.37% | -54.60% | -79.83% | -106.95% | -112.94% | -158.10% | -145.18% |
| ROE | -165.57% | -615.10% | -132.97% | -247.15% | -309.65% | -165.57% | -58.73% | -72.43% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 2.9x |
| 1.0x |
| — |
| 45.86% |
| $31.69M |
| YI111, Inc. | $3.51 | — | — | — | -14.84% | $30.88M |
| IGCIGC Pharma, Inc. | $0.31 | — | 5.2x | — | -83.34% | $32.05M |